Ascendis Pharma A (ASND) Convertible Debt (2022 - 2025)

Ascendis Pharma A (ASND) has 3 years of Convertible Debt data on file, last reported at $499.8 million in Q4 2025.

• For the quarter ending Q4 2025, Convertible Debt rose 2.08% year-over-year to $499.8 million; the trailing twelve-month figure through Dec 2025 stood at $499.8 million (up 2.08% YoY), and the FY2025 full-year result was $499.8 million, up 0.79% from the prior year.
• Convertible Debt improved to $499.8 million in Q4 2025, from $489.6 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $499.8 million in Q4 2025 to a low of $407.3 million in Q4 2022.
• A 3-year average of $465.6 million and a median of $489.6 million in 2024 frame the typical range for Convertible Debt.
• Peak annual rise in Convertible Debt reached 2.08% in 2025, while the deepest fall reached 2.08% in 2025.
• Tracing ASND's Convertible Debt over 3 years: stood at $407.3 million in 2022, then grew by 20.22% to $489.6 million in 2024, then rose by 2.08% to $499.8 million in 2025.
• Business Quant data shows ASND's Convertible Debt at $499.8 million in Q4 2025, $489.6 million in Q4 2024, and $407.3 million in Q4 2022.